Overall survival , time to progression , and objective response rate were 10.9 vs. 11.3 months ( P = .7353 ) , 4.7 vs. 4.4 months , and 74.2 % ( 23 of 31 ) vs. 60.0 % ( 18 of 30 ) , respectively , and quality of life showed no significant difference between the 2 arms .